A team of researchers at the IRCM, supervised by Dr. Jacques Drouin, reprogrammed the identity of cells in the pituitary gland and identified critical mechanisms of epigenetic cell programming. This important discovery, published today by the scientific journal Genes & Development, could eventually lead to new pharmacological targets for the treatment of Cushing’s disease.
Dr. Drouin’s team studies the pituitary gland, which is the master gland located at the base of the skull that secretes hormones to control all other glands of the endocrine system. Disruption of pituitary functions has dire consequences on growth, reproduction and metabolism.
Within the pituitary gland, each hormone is produced by cells of a different lineage. Unique cell identities are created by cell-specific genetic programs that are implemented during development. Appropriate cell programming is a critical process that needs to be harnessed in order to exploit the therapeutic benefits of stem cell research.
In their work, the IRCM researchers showed that the transcription factor Pax7 has pioneering abilities, meaning that it is able to open the tightly-packed chromatin structure of specific regions of the genome. This unmasking of a subset of the genome’s regulatory sequences changes the genome’s response to differentiation signals such that different cell types are generated.
“We reprogrammed the identity of pituitary cells by using the Pax7 gene in order to create two different types of cells,” says Lionel Budry, former student in Dr. Drouin’s laboratory and first author of the article. “This allowed us to show that the Tpit protein produces different cell lineages according to the presence or absence of Pax7, and its impact on chromatin organisation.”
Cushing’s disease is caused by small tumours of the pituitary gland that produce excessive amounts of hormones. For patients with this disease, the abnormal hormone production can lead to hypertension, obesity, diabetes and osteoporosis.
“For approximately 10% of patients suffering from Cushing’s disease, we found that the disease-causing tumours contain cells that express the Pax7 protein,” explains Dr. Drouin, Director of the Molecular Genetics research unit at the IRCM. “No effective pharmacological treatment currently exists for Cushing’s disease. This discovery could ultimately lead to the development of such treatment, based on tumour growth inhibition by hormones, similarly to what is already done for other pituitary tumours like lactotrope adenomas.”About the research project
For more information on this discovery, please refer to the article summary published online by Genes & Development.About Dr. Jacques Drouin
For more information and to schedule an interview with Dr. Drouin, please contact:Julie Langelier
Julie Langelier | EurekAlert!
New image of a cancer-related enzyme in action helps explain gene regulation
05.06.2020 | Penn State
Protecting the Neuronal Architecture
05.06.2020 | Universität Heidelberg
Humans rely dominantly on their eyesight. Losing vision means not being able to read, recognize faces or find objects. Macular degeneration is one of the major...
In meningococci, the RNA-binding protein ProQ plays a major role. Together with RNA molecules, it regulates processes that are important for pathogenic properties of the bacteria.
Meningococci are bacteria that can cause life-threatening meningitis and sepsis. These pathogens use a small protein with a large impact: The RNA-binding...
An analysis of more than 200,000 spiral galaxies has revealed unexpected links between spin directions of galaxies, and the structure formed by these links...
Two prominent X-ray emission lines of highly charged iron have puzzled astrophysicists for decades: their measured and calculated brightness ratios always disagree. This hinders good determinations of plasma temperatures and densities. New, careful high-precision measurements, together with top-level calculations now exclude all hitherto proposed explanations for this discrepancy, and thus deepen the problem.
Hot astrophysical plasmas fill the intergalactic space, and brightly shine in stellar coronae, active galactic nuclei, and supernova remnants. They contain...
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
05.06.2020 | Life Sciences
05.06.2020 | Physics and Astronomy
05.06.2020 | Life Sciences